Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

Stimulus hopes are rapidly meeting reality and a 30% gain is worth booking

HSBC MSCI China (HMCH) 546.5p

Gain to date: 30.4%


We flagged this exchange-traded fund back in January noting how out of favour the China was and how this was a low-cost way of gaining exposure to big Chinese stocks.

WHAT HAS HAPPENED SINCE WE SAID TO BUY?

For a while, very little. The ETF (and the MSCI China index it tracks) eked out some modest gains in the spring before the Chinese equity story lost momentum again. However, the promise of major stimulus from Beijing, as it looks to hit its 5% annual GDP growth target, proved a major catalyst in late September.

Measures announced included a lending pool to help fund managers, insurers and brokers buy more stock and initiate share buybacks as well as moves to stimulate a struggling Chinese property market.

Meanwhile, in mid-October the finance ministry pledged to ‘significantly increase’ debt to boost the economy and announced proposals to help stoke consumer demand.

While some of the initial excitement has faded, we are still up more than 30% on our initial entry point.

WHAT SHOULD INVESTORS DO NOW?

We think they should book this profit. The stimulus announcements haven’t stood up that well to closer examination, with analysts at investment bank Jefferies noting: ‘As stimulus hopes meet the reality, companies with the worst channel health face more risks. The recent market rally thus looks increasingly unjustifiable.’

We would agree and also believe that any exposure to China should be tactical rather than long term. We see significant geopolitical risks in the future and would also note China faces substantial demographic challenges which are more akin to those faced in the West than other emerging economies. A legacy of its longstanding one-child policy which means achieving material economic growth could be a major challenge.

For those who continue to want Chinese exposure this remains a perfectly good product, but for the reasons detailed above it is not one we would recommend buying at this point.

‹ Previous2024-10-17Next ›